ArticleFrontiers in oncology2025
A discrete choice experiment analysis to understand patient preferences for multiple myeloma treatments.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Patients', clinicians' and research's priorities on important outcomes in multiple myeloma: A mixed-methods study.British journal of haematology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple myeloma (MM) is a malignant plasma cell disorder characterized by the clonal expansion of abnormal plasma cells within the bone marrow. The management of relapsed/refractory multiple myeloma (RRMM) represents a significant challenge as the disease relapses or becomes refractory to previous treatments. Recent advances in therapy have expanded RRMM treatment options. This study aimed to gain a deeper understanding of patients' treatment preferences regarding available therapeutic options. Methods: This study was designed as a non-interventional descriptive cross-sectional study based on an online discrete choice experiment (DCE) among adult RRMM patients living in the between USA November 2023 and March 2024. The survey included attributes and levels derived from an extensive literature review and guided interviews conducted with MM patients. Preference data were analyzed using a conditional logistic (CL) regression model and relative attribute importance (RAI) scores were calculated. Patients' willingness to trade off overall response rate (ORR) was evaluated using the partworth utilities estimated from the CL model. Results: 149 MM patients completed the survey; 66% had received 1-2 prior lines of therapy, 15% three prior lines, 19% four or more prior lines. Patients significantly preferred treatments with longer progression-free survival (PFS) and overall survival (OS) and higher ORR (RAI: 36.4% and 22.1%, respectively). With respect to adverse events assessed in this study, patients expressed concern for cytokine release syndrome (CRS) (RAI: 15.2%) and infections (RAI: 11.9%). In contrast, nail/skin disorders, duration of hospitalization, and taste disorder were less important to patients. Patients would be willing to accept a high risk of CRS (72% over no risk) to gain 29% increase in ORR. Conclusions: Patients showed a clear preference for treatment efficacy (PFS/OS and ORR). This study confirmed patients' valuation on treatment attributes in the new treatment landscape and highlighted the importance of shared treatment decision-making for optimal clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.